

Special Issue

Vaccines and Prevention of Infections in Early Life

Message from the Guest Editor

The focus on the well-being of our population begins in the neonatal period and early infancy. Early-life infections have high mortality and morbidity and may have a tremendous negative impact on our health rates. Significant progress has been made towards the prevention of infections in early life. However, there are still many challenges to overcome. Infections from pathogens continue to pose a significant burden for neonates and young infants. Extensive research focuses on the development of novel maternal vaccines and ways to boost maternal immunity and placental antibody transfer to protect the offspring. Apart from maternal vaccines, there are also other preventive measures under investigation that may be employed. There are still unanswered questions on the acceptance and implementation of the existing maternal vaccines, as well as their impact on the infant's immunity and immune responses to other vaccines. Further research on the epidemiology of early-life infections, screening strategies and preventive measures that will advance our understanding and reduce the instances of disease in this population is of great importance.

Guest Editor

Dr. Eleni Vergadi

Department of Mother and Child, School of Medicine, University of Crete, 71003 Heraklion, Greece

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/146351

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).